Vancouver, BC – May 05, 2015 – InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, announced today that former GW Pharmaceuticals financier, investor, and Non-Executive Director, Peter Mountford, has agreed to support InMed as Strategic Advisor with primary responsibility for the European markets.
In this role, Mr. Mountford will leverage his previous success in the emerging field of cannabinoid biotech, providing capital markets counsel and advisory for InMed, as well as enhancing shareholder value by advising the Company on European financing opportunities. As a financier, early stage investor, and Non-Executive Director for GW Pharmaceuticals, Mr. Mountford was successful in assisting the company with raising a substantial level of funds for the successful development of its business and was instrumental in its 2001 initial public offering (IPO).
Peter Mountford commented, “I am attracted to InMed’s growing therapeutic pipeline and accelerated development strategy, as well as the impressive team of executives and advisors that the company has assembled. Their cutting-edge approach of therapy identification and development based on their proprietary platform technology is particularly compelling. As the market for cannabinoid-based therapeutics continues to expand globally, I look forward to supporting InMed with the expectation that my significant experience investing directly and securing investments in this sector will result in enhanced visibility for the company among European investors.”
Craig Schneider, President and CEO of InMed, remarked “Aligning InMed with Peter Mountford brings another highly influential leader in cannabinoid based therapy development to our company. Specifically, we look forward to benefitting from Peter’s proven financing capabilities and deep knowledge of European investors as we seek to expand InMed’s shareholder base and attract new capital.”
Mr. Mountford is currently a Non-Executive Director of RWS Holdings plc, one of the world’s leading patent translation and search companies, and one of the top 50 companies on AIM, the London Stock Exchange’s highly successful market for smaller growing companies. Mr. Mountford was instrumental in the IPO of RWS in 2003, and since then its share price has grown more than six times. More recently, Mr. Mountford was one of the founders of Learning Technologies Group plc, Europe’s leading e-learning company, whose share price has risen almost four times since its successful IPO in 2013. Mr. Mountford has invested in and helped many companies raise large amounts of capital from Private Equity funds, pre-IPO investors, and Institutional Investors (through IPOs and reversals into cash shells). He is highly experienced in all areas of corporate finance including fund-raising, acquisitions, disposals, MBOs, MBIs and flotations.
InMed is a clinical stage biopharmaceutical company that specializes in developing cannabis based therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.
For more information, please visit our website at www.inmedpharma.com
InMed Pharmaceuticals Inc.
President and Chief Executive Officer
VP Corporate Development
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)
Amy Wheeler (Media)
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about Peter Mountford supporting InMed as a financial advisor for the European markets; Mr. Mountford enhancing shareholder value and Company visibility by introducing the Company to key European investors; expanding InMed’s shareholder base and attracting new capital; and the fundamental value drivers of the company. With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the continued availability of Mr. Mountford; the effectiveness of Mr. Mountford in reaching European investors; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: Mr. Mountford may become unavailable; Mr. Mountford’s efforts to bring in valuable European investors may not be as successful as anticipated, or at all; InMed’s proprietary platform technology, product pipeline and accelerated development pathway may not return their expected level of value; and economic or market conditions may worsen.
A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s continuous disclosure filings with Canadian securities regulatory authorities at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.